Skip to main content
Figure 1 | Molecular Cancer

Figure 1

From: Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line

Figure 1

Effect of dasatinib on TPC-1 cells. (A) Left, phosphotyrosine protein profiles of TPC-1 cells treated with various dasatinib concentrations (100, 300, and 1000 nM). Right, Src and FAK phosphorylation status following dasatinib treatment. Results were normalized by comparison with beta-actin. (B) Proliferation assay. Left, proliferation curves of TPC-1 cells treated with 100 nM, 300 nM, and 1000 nM dasatinib after 24, 48, and 72 hours. Right, statistical visualization of the proliferation curves. After 72 hours, the TPC-1 cell proliferation was significantly (p < 0.001) reduced by 60%, 65%, and 75% after treatment with 100 nM, 300 nM, and 1000 nM dasatinib, respectively.

Back to article page

Molecular Cancer

ISSN: 1476-4598

Contact us